MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
Abstract
The effectiveness of immunotherapy targeting the immune checkpoint PD-L1/PD-1 pathway highlights importance of elucidating the regulatory mechanisms of PD-L1 expression in cancer cells. Previous studies demonstrate that oncogene MYC up-regulates PD-L1 expression in lymphomas. In the present study, we investigated the regulatory role of MYC in the PD-L1 expression induced by IFN-γ in HCC cells. Unexpectedly, knockdown of MYC expression using siRNA assay increased the inducible expression of PD-L1 both at mRNA and protein levels. Mechanistically, the inhibition of MYC elevated expression of STAT1, a critical component of IFN-γ signaling pathway, leading to the elevation of PD-L1 expression in HCC cells exposed to IFN-γ. These results suggest that MYC may down-regulate PD-L1 expression in the context of HCC. This study implicates that a combination therapy targeting MYC function and PD-L1/PD-1 pathway might be effective for treatment of HCC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Perturbation of MYC and CUL3 both increased PD-L1 protein levels, consistent with previous reports.
“we verified that perturbation of BHLH transcription factor MYC [12] and the ubiquitin ligase CUL3 [15] both increased PD-L1 protein levels, consistent with previous reports.”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [12]
Cites
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works
Papalexi, E., Mimitou, E. P., Butler, A. W., Foster, S., Bracken, B., Mauck, W. M., Wessels, H.-H., Hao, Y., Yeung, B. Z., Smibert, P., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00778-2 · Cited by 238 · see citing works
- Authors
- Zou, J., Zhuang, M., Yu, X., Li, N., Mao, R., Wang, Z., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y.
- Affiliations
- Shandong University (CN)
- Corresponding author
- Shi, Yongyu
- ORCID
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 101
- Pages
- 203-209
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W2878292361
- Cited by
- 54
- References
- 1
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 14 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 1
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Key Technology Research and Development Program of Shandong (2017GSF218066)
- National Aerospace Science Foundation of China (81372264, 81672806)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- c-Myc, PD-L1 expression, interferon-gamma, hepatocellular carcinoma, STAT1, PD-1/PD-L1 immune checkpoint, cancer immunotherapy, combination therapy
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Interferon-gamma, Liver Neoplasms, Transcription, Genetic, Signal Transduction, Proto-Oncogene Proteins c-myc, Cell Line, Tumor, STAT1 Transcription Factor, Gene Knockdown Techniques, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review